{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:22:48Z","timestamp":1791206568065,"version":"4.1.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,10,2]],"date-time":"2014-10-02T00:00:00Z","timestamp":1412208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1007\/s00520-014-2437-3","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T21:02:55Z","timestamp":1412110975000},"page":"237-247","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Burden of skeletal-related events in prostate cancer: unmet need in pain improvement"],"prefix":"10.1007","volume":"23","author":[{"given":"M. S.","family":"Broder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Cherepanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Linhares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,10,2]]},"reference":[{"key":"2437_CR1","unstructured":"National Cancer Institute. What You Need To Know About\u2122 Prostate Cancer. Last accessed, 9\/25\/2014: http:\/\/www.cancer.gov\/cancertopics\/"},{"key":"2437_CR2","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMcp1103642","volume":"365","author":"RM Hoffman","year":"2011","unstructured":"Hoffman RM (2011) Clinical practice. Screening for prostate cancer. N Engl J Med 365:2013\u20132019","journal-title":"N Engl J Med"},{"key":"2437_CR3","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1089\/jpm.2011.0219","volume":"15","author":"S Yennurajalingam","year":"2012","unstructured":"Yennurajalingam S, Atkinson B, Masterson J, Urbauer D, Tu SM, Bruera E (2012) The impact of an outpatient palliative care consultation on symptom burden in advanced prostate cancer patients. J Palliat Med 15:20\u201324","journal-title":"J Palliat Med"},{"key":"2437_CR4","unstructured":"American Cancer Society. Prostate Cancer. Last accessed, 9\/25\/2014: http:\/\/www.cancer.org\/Cancer\/ProstateCancer\/index"},{"key":"2437_CR5","unstructured":"Rove KO, Crawford ED (2011) Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival. Oncology 25:1362\u20131370, 1375\u20131381, 1387"},{"key":"2437_CR6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27:165\u2013176","journal-title":"Cancer Treat Rev"},{"key":"2437_CR7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","volume":"16","author":"L Costa","year":"2008","unstructured":"Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence. Support Care Cancer 16:879\u2013889","journal-title":"Support Care Cancer"},{"key":"2437_CR8","unstructured":"United States Food and Drug Administration. FDA Public Workshop on Clinical Trial Endpoints in Prostate Cancer. June 21\u201322, 2004. Bethesda, Maryland. Last accessed, 9\/25\/2014: http:\/\/www.fda.gov\/downloads\/AboutFDA\/CentersOffices\/CDER\/ucm120857.pdf"},{"key":"2437_CR9","unstructured":"European Medicines Agency. Evaluation of Medicines for Human Use. Assessment Report for Zometa. International non-proprietary name\/Common name: zoledronic acid. Proc. No. EMEA\/H\/C\/000336\/II\/0031. Doc. Ref No: EMA\/35729\/2010. Last accessed, 9\/25\/2014: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000336\/WC500074897.pdf"},{"key":"2437_CR10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M N\u00f8rgaard","year":"2010","unstructured":"N\u00f8rgaard M, Jensen A, Jacobsen JB, Cetin K, Fryzek JP, S\u00f8rensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 184:162\u2013167","journal-title":"J Urol"},{"key":"2437_CR11","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","volume":"15","author":"V DePuy","year":"2007","unstructured":"DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F (2007) Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15:869\u2013876","journal-title":"Support Care Cancer"},{"key":"2437_CR12","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","volume":"94","author":"F Saad","year":"2002","unstructured":"Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group (2002) A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94:1458\u20131468","journal-title":"J Natl Cancer Inst"},{"key":"2437_CR13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","volume":"16","author":"KP Weinfurt","year":"2005","unstructured":"Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579\u2013584","journal-title":"Ann Oncol"},{"key":"2437_CR14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.radonc.2004.12.001","volume":"74","author":"N Aass","year":"2005","unstructured":"Aass N, Foss\u00e5 SD (2005) Pre- and post-treatment daily life function in patients with hormone resistant prostate carcinoma treated with radiotherapy for spinal cord compression. Radiother Oncol 74:259\u2013265","journal-title":"Radiother Oncol"},{"key":"2437_CR15","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1002\/cncr.20756","volume":"103","author":"YM Linden van der","year":"2005","unstructured":"van der Linden YM, Dijkstra SP, Vonk EJ, Marijnen CA, Leer JW, Dutch Bone Metastasis Study Group (2005) Prediction of survival in patients with metastases in the spinal column. Cancer 103:320\u2013328","journal-title":"Cancer"},{"key":"2437_CR16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/02841860802488128","volume":"48","author":"RS Berg","year":"2009","unstructured":"Berg RS, Yilmaz MK, H\u00f8yer M, Keldsen N, Nielsen OS, Ewertz M (2009) Half body irradiation of patients with multiple bone metastases: a phase II trial. Acta Oncol 48:556\u2013561","journal-title":"Acta Oncol"},{"key":"2437_CR17","first-page":"35","volume":"1","author":"WE Hamouda","year":"2007","unstructured":"Hamouda WE, Roshdy W, Teema M (2007) Single versus conventional fractionated radiotherapy in the palliation of painful bone metastases. Gulf J Oncol 1:35\u201341","journal-title":"Gulf J Oncol"},{"key":"2437_CR18","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/jnci\/dji139","volume":"97","author":"WF Hartsell","year":"2005","unstructured":"Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M (2005) Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97:798\u2013804","journal-title":"J Natl Cancer Inst"},{"key":"2437_CR19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ijrobp.2008.10.044","volume":"75","author":"A Hird","year":"2009","unstructured":"Hird A, Chow E, Zhang L, Wong R, Wu J, Sinclair E, Danjoux C, Tsao M, Barnes E, Loblaw A (2009) Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three Canadian cancer centers. Int J Radiat Oncol Biol Phys 75:193\u2013197","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2437_CR20","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3171\/SPI\/2008\/8\/3\/271","volume":"8","author":"A Ibrahim","year":"2008","unstructured":"Ibrahim A, Crockard A, Antonietti P, Boriani S, B\u00fcnger C, Gasbarrini A, Grejs A, Harms J, Kawahara N, Mazel C, Melcher R, Tomita K (2008) Does spinal surgery improve the quality of life for those with extradural (spinal) osseous metastases? An international multicenter prospective observational study of 223 patients. J Neurosurg Spine 8:271\u2013278","journal-title":"J Neurosurg Spine"},{"key":"2437_CR21","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1245\/s10434-008-0011-2","volume":"16","author":"B Liberman","year":"2009","unstructured":"Liberman B, Gianfelice D, Inbar Y, Beck A, Rabin T, Shabshin N, Chander G, Hengst S, Pfeffer R, Chechick A, Hanannel A, Dogadkin O, Catane R (2009) Pain palliation in patients with bone metastases using MR-guided focused ultrasound surgery: a multicenter study. Ann Surg Oncol 16:140\u2013146","journal-title":"Ann Surg Oncol"},{"key":"2437_CR22","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0360-3016(01)01495-X","volume":"50","author":"OM Salazar","year":"2001","unstructured":"Salazar OM, Sandhu T, da Motta NW, Escutia MA, Lanz\u00f3s-Gonzales E, Mouelle-Sone A, Moscol A, Zaharia M, Zaman S (2001) Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized phase III trial of the international atomic energy agency (IAEA). Int J Radiat Oncol Biol Phys 50:765\u2013775","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2437_CR23","first-page":"1","volume":"2","author":"WM Sze","year":"2008","unstructured":"Sze WM, Shelley M, Held I, Mason M (2008) Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy (review). Cochrane Database Syst Rev 2:1\u201332","journal-title":"Cochrane Database Syst Rev"},{"key":"2437_CR24","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860\u20131867","journal-title":"Cancer"},{"key":"2437_CR25","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0022-5347(05)00241-7","volume":"175","author":"D Rades","year":"2006","unstructured":"Rades D, Stalpers LJA, Veninga T, Rudat V, Schulte R, Hoskin PJ (2006) Evaluation of functional outcome and local control after radiotherapy for metastatic spinal cord compression in patients with prostate cancer. J Urol 175:552\u2013556","journal-title":"J Urol"},{"issue":"2","key":"2437_CR26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/107327481201900208","volume":"19","author":"M Tomblyn","year":"2012","unstructured":"Tomblyn M (2012) The role of bone-seeking radionuclides in the palliative treatment of patients with painful osteoblastic skeletal metastases. Cancer Control 19(2):137\u2013144","journal-title":"Cancer Control"},{"key":"2437_CR27","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MNM.0b013e32805b72a0","volume":"28","author":"M B\u0105czyk","year":"2007","unstructured":"B\u0105czyk M, Czepczy\u0144ski R, Milecki P, Pisarek M, Oleska R, Sowi\u0144ski J (2007) 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nucl Med Commun 28:245\u2013250","journal-title":"Nucl Med Commun"},{"key":"2437_CR28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s002590100533","volume":"28","author":"A Dafermou","year":"2001","unstructured":"Dafermou A, Colamussi P, Giganti M, Cittanti C, Bestagno M, Piffanelli A (2001) A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur J Nucl Med 28:788\u2013798","journal-title":"Eur J Nucl Med"},{"key":"2437_CR29","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2008.18.9811","volume":"27","author":"K Fizazi","year":"2009","unstructured":"Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A (2009) Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 27:2429\u20132435","journal-title":"J Clin Oncol"},{"key":"2437_CR30","first-page":"1150","volume":"43","author":"SH Han","year":"2002","unstructured":"Han SH, de Klerk JMH, Tan S, van het Schip AD, Derksen BH, van Dijk A, Kruitwagen CL, Blijham GH, van Rijk PP, Zonnenberg BA (2002) The Placorhen study: a double-blind, placebo-controlled, randomized radionuclide study with 186re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. J Nucl Med 43:1150\u20131156","journal-title":"J Nucl Med"},{"key":"2437_CR31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjc.6601158","volume":"89","author":"K Liepe","year":"2003","unstructured":"Liepe K, Kropp J, Runge R, Kotzerke J (2003) Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br J Cancer 89:625\u2013629","journal-title":"Br J Cancer"},{"key":"2437_CR32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s00432-004-0625-0","volume":"131","author":"K Liepe","year":"2005","unstructured":"Liepe K, Runge R, Kotzerke J (2005) The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol 131:60\u201366","journal-title":"J Cancer Res Clin Oncol"},{"key":"2437_CR33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/104990910502200613","volume":"22","author":"K Liepe","year":"2005","unstructured":"Liepe K, Runge R, Kotzerke J (2005) Systemic radionuclide therapy in pain palliation. Am J Hosp Palliat Care 22:457\u2013464","journal-title":"Am J Hosp Palliat Care"},{"key":"2437_CR34","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/MNM.0b013e32825a6adc","volume":"28","author":"K Liepe","year":"2007","unstructured":"Liepe K, Kotzerke J (2007) A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun 28:623\u2013630","journal-title":"Nucl Med Commun"},{"key":"2437_CR35","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1158\/1078-0432.CCR-04-2244","volume":"11","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Larsen RH, Foss\u00e5 SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005) First clinical experience with \u03b1-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11:4451\u20134459","journal-title":"Clin Cancer Res"},{"key":"2437_CR36","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jpainsymman.2004.07.008","volume":"29","author":"S Nilsson","year":"2005","unstructured":"Nilsson S, Strang P, Ginman C, Zimmermann R, Edgren M, Nordstr\u00f6m B, Ryberg M, K\u00e4lkner KM, Westlin JE (2005) Palliation of bone pain in prostate cancer using chemotherapy and strontium-89: a randomized phase II study. J Pain Symptom Manag 29:352\u2013357","journal-title":"J Pain Symptom Manag"},{"key":"2437_CR37","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2003.12.060","volume":"21","author":"H Palmedo","year":"2003","unstructured":"Palmedo H, Manka-Waluch A, Albers P, Schmidt-Wolf IG, Reinhardt M, Ezziddin S, Joe A, Roedel R, Fimmers R, Knapp FF Jr, Guhlke S, Biersack HJ (2003) Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate. J Clin Oncol 21:2869\u20132875","journal-title":"J Clin Oncol"},{"key":"2437_CR38","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.urology.2004.01.034","volume":"63","author":"O Sartor","year":"2004","unstructured":"Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P, Quadramet 424Sm10\/11 Study Group (2004) Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 63:940\u2013945","journal-title":"Urology"},{"key":"2437_CR39","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/cncr.22431","volume":"109","author":"O Sartor","year":"2007","unstructured":"Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ (2007) Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer 109:637\u2013643","journal-title":"Cancer"},{"key":"2437_CR40","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/0019-509X.25890","volume":"43","author":"M Tripathi","year":"2006","unstructured":"Tripathi M, Singhal T, Chandrasekhar N, Kumar P, Bal C, Jhulka PK, Bandopadhyaya G, Malhotra A (2006) Samarium-153 ethylenediamine tetramethylene phosphonate therapy for bone pain palliation in skeletal metastases. Indian J Cancer 43:86\u201392","journal-title":"Indian J Cancer"},{"key":"2437_CR41","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/bjoc.2000.1610","volume":"84","author":"SL Turner","year":"2001","unstructured":"Turner SL, Gruenewald S, Spry N, Gebski V, Metastron Users Group (2001) Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer 84:297\u2013302","journal-title":"Br J Cancer"},{"key":"2437_CR42","first-page":"63","volume":"47","author":"MP Yaneva","year":"2005","unstructured":"Yaneva MP, Semerdjieva M, Radev LR, Ivanova EK, Geiman M, Vlaikova MI, Mihova LS (2005) Radionuclide therapy of cancer patients with bone metastases. Folia Med 47:63\u201369","journal-title":"Folia Med"},{"key":"2437_CR43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00259-009-1243-5","volume":"37","author":"A Zafeirakis","year":"2010","unstructured":"Zafeirakis A, Papatheodorou G, Arhontakis A, Gouliamos A, Vlahos L, Limouris GS (2010) Predictive implications of bone turnover markers after palliative treatment with 186Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases. Eur J Nucl Med Mol Imaging 37:103\u2013113","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2437_CR44","first-page":"211","volume":"48","author":"AH Leondi","year":"2004","unstructured":"Leondi AH, Souvatzoglou MA, Rapti AS, Leontopoulou SA, Papadaki EK, Datseris EI, Anagnostopoulou US, Zerva CJ (2004) Palliative treatment of painful bone metastases with 186rhenium-HEDP in patients with lung cancer. Q J Nucl Med Mol Imaging 48:211\u2013219","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"2437_CR45","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(07)70147-X","volume":"8","author":"S Nilsson","year":"2007","unstructured":"Nilsson S, Franz\u00e9n L, Parker C, Tyrrell C, Blom R, Tennvall J, Lennern\u00e4s B, Petersson U, Johannessen DC, Sokal M, Pigott K, Yachnin J, Garkavij M, Strang P, Harmenberg J, Bolstad B, Bruland OS (2007) Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. Lancet Oncol 8:587\u2013594","journal-title":"Lancet Oncol"},{"key":"2437_CR46","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/00365590410002528","volume":"39","author":"M J\u00f8nler","year":"2005","unstructured":"J\u00f8nler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, Hedelin H, Wald\u00e9n M, Scandinavian Prostate Cancer Group Study 5 Study Group (2005) Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: results from the Scandinavian Prostate Cancer Group Study 5. Scand J Urol Nephrol 39:42\u201348","journal-title":"Scand J Urol Nephrol"},{"key":"2437_CR47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.9-6-687","volume":"9","author":"CL Vogel","year":"2004","unstructured":"Vogel CL, Yanagihara RH, Wood AJ, Schnell FM, Henderson C, Kaplan BH, Purdy MH, Orlowski R, Decker JL, Lacerna L, Hohneker JA (2004) Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy. Oncologist 9:687\u2013695","journal-title":"Oncologist"},{"key":"2437_CR48","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1111\/j.1464-410X.2008.08283.x","volume":"103","author":"S Oudard","year":"2009","unstructured":"Oudard S, Banu E, Medioni J, Scotte F, Banu A, Levy E, Wasserman J, Kacso G, Andrieu JM (2009) What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int 103:1641\u20131646","journal-title":"BJU Int"},{"key":"2437_CR49","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","volume":"2","author":"CM Tangen","year":"2003","unstructured":"Tangen CM, Faulkner JR, Crawford ED, Thompson IM, Hirano D, Eisenberger M, Hussain M (2003) Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2:41\u201345","journal-title":"Clin Prostate Cancer"},{"key":"2437_CR50","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1179\/joc.2005.17.5.555","volume":"17","author":"F Fulfaro","year":"2005","unstructured":"Fulfaro F, Leto G, Badalamenti G, Arcara C, Cicero G, Valerio MR, Di Fede G, Russo A, Vitale A, Rini GB, Casuccio A, Intrivici C, Gebbia N (2005) The use of zoledronic acid in patients with bone metastases from prostate carcinoma: effect on analgesic response and bone metabolism biomarkers. J Chemother 17:555\u2013559","journal-title":"J Chemother"},{"key":"2437_CR51","unstructured":"(2010) PROLIA (denosumab) [package insert]. Thousand Oaks, California: Amgen Inc"},{"key":"2437_CR52","doi-asserted-by":"crossref","unstructured":"Agarwal N, Di Lorenzo G, Sonpavde G, Bellmunt J (2014) New agents for prostate cancer. Ann Oncol. Mar 20","DOI":"10.1093\/annonc\/mdu038"},{"issue":"4","key":"2437_CR53","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00520-011-1356-9","volume":"20","author":"LS Matza","year":"2012","unstructured":"Matza LS, Fallowfield LJ, Chung KC, Currie BM, Van Brunt K, Patrick DL (2012) Patient-reported outcome instruments used to assess pain and functioning in studies of bisphosphonate treatment for bone metastases. Support Care Cancer 20(4):657\u2013677. doi: 10.1007\/s00520-011-1356-9 , Review","journal-title":"Support Care Cancer"},{"issue":"1","key":"2437_CR54","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12955-014-0104-5","volume":"12","author":"MJ Clark","year":"2014","unstructured":"Clark MJ, Harris N, Griebsch I, Kaschinski D, Copley-Merriman C (2014) Patient-reported outcome labeling claims and measurement approach for metastatic castration-resistant prostate cancer treatments in the United States and European Union. Health Qual Life Outcomes 12(1):104","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"2437_CR55","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/cncr.28470","volume":"120","author":"E Basch","year":"2014","unstructured":"Basch E, Trentacosti AM, Burke LB, Kwitkowski V, Kane RC, Autio KA, Papadopoulos E, Stansbury JP, Kluetz PG, Smith H, Justice R, Pazdur R (2014) Pain palliation measurement in cancer clinical trials: the US Food and Drug Administration perspective. Cancer 120(5):761\u2013767. doi: 10.1002\/cncr.28470","journal-title":"Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2437-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-014-2437-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-014-2437-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T13:35:18Z","timestamp":1565876118000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-014-2437-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,2]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1007\/s00520-014-2437-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,2]]}}}